



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

B173 CIP

Applicants : Thalia Papayannopoulou
Serial No. : 08/436,339
Filed : July 13, 1995
For : PERIPHERALIZATION OF HEMATOPOIETIC STEM CELLS
Group Art Unit : Not Yet Assigned
Examiner : Not Yet Assigned

New York, New York
November 3, 1995

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted:

- ☐ within three months of the application filing date;
- ☒ more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.98, submission of this Statement requires no fee. However, if for any reason a fee is due, the Commissioner is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

James F. Haley, Jr. (Reg. No. 27,794)
Immac J. Thampoe (Reg. No. 36,322)
Attorneys for Applicant
c/o FISH & NEAVE

I hereby Certify that this Correspondence is being Deposited with the U.S. Postal Service as First Class Mail in an Envelope Addressed to: ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON D.C. 20231, on

November 3, 1995



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
 Group Art Unit : Not Yet Assigned
 Applicants : Thalia Papayannopoulou
 Serial No. : 08/436,339
 Filed : July 13, 1995
 For : PERIPHERALIZATION OF HEMATOPOIETIC STEM CELLS

New York, New York
 November 3, 1995

Hon. Assistant Commissioner
 for Patents
 Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicant makes of record the following documents. For the convenience of the Examiner, applicant has enclosed a completed Form PTO-1449 listing these documents.

UNITED STATES PATENTS

5,061,620 10/29/91 Tsukamoto et al.

OTHER PATENT PUBLICATIONS

*EP 0 455 482 11/06/91

ARTICLES

Andrews et al., "A C-Kit Ligand, Recombinant Human Stem Cell Factor, Mediates Reversible Expansion of Multiple CD34+ Colony-Forming Cell Types In Blood and Marrow of Baboons", Blood, 80, pp. 920-927 (1992).

*Bensinger et al., "Autologous Transplantation With Peripheral Blood Mononuclear cells Collected After Administration of Recombinant Granulocyte Stimulating Factor", Blood, 81, pp. 1111-1116 (1993).

*Berenson, "Transplantation of CD34+ Hematopoietic Precursors: Clinical Rationale", Transplantation Proceedings, 24, No. 6, pp. 3032-3034 (1992).

*Bregni et al., "Human Peripheral Blood Hematopoietic Progenitors Are Optimal Targets of Retroviral-Mediated Gene Transfer", Blood, 80, No. 6, pp. 1418-1422 (1992).

*Brugger et al., "Ex Vivo Expansion of Enriched Peripheral Blood CD34+ Progenitor Cells by Stem Cell Factor, Interleukin-18 (IL-18), IL-6, IL-3, Interferon- , and Erythropoietin", Blood, 81, No. 10, pp. 2579-2584 (1993).

Bronchud et al., "In Vitro and In Vivo Analysis of the Effects of Recombinant Human Granulocyte Colony-Stimulating Factor in Patients", Br.J.Cancer, 58, pp. 64-69 (1988).

*Chao et al., "Granulocyte Colony-Stimulating Factor 'Mobilized' Peripheral Blood Progenitor Cells Accelerate Granulocyte and Platelet Recovery After High-Dose Chemotherapy", Blood, 81, No. 8, pp. 2031-2035 (1993).

Craig et al., "Peripheral Blood Stem Cell Transplantation", Blood Review, 6:, pp. 59-67 (1992).

DePalma, "CellPro, Inc. Tests Its Stem Cell-Therapy in Clinical Trials", Genetic Engineering News, Vol. 12 (05/01/92).

Denkers et al., "VLA Molecule Express May Be Involved in the Release of Acute Myeloid Leukaemic Cells From the Bone Marrow", Leukemia Research, 16, pp. 469-474 (1992).

Edgington, "New Horizons for Stem-Cell Bioreactors", Biotechnology, 10, pp. 1099-1106 (1992).

*Gale et al., "Blood Stem Cell Transplants Come of Age", Bone Marrow Transplantation, 9, pp. 151-155 (1992).

Gerhartz, "Zukunftsperspektiven von Knochenmarkund Stammzellaktivierung fur die autologe Transplantation", Beitr Infusionther, 28, pp. 254-309 (1991).

Haas, "Successful Autologous Transplantation of Blood Stem Cells Mobilized with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor", Exp. Hematol., 18, pp. 94-98 (1990).

*Kessinger et al., "The Evolving Role of Autologous Peripheral Stem Cell Transplantation Following High-Dose Therapy for Malignancies", Blood, 77, No. 2, pp. 211-213 (1991).

Korbling, "Die Rolle der Stammzell-Mobilisation im Rahmen der Autologen Blutstammzell-Transplantation", Beitr. Infusionther., 28, 233-241 (1991).

Liesveld et al., "Expression of Integrins and Examination of Their Adhesive Function in Normal and Leukemic Hematopoietic Cells", Blood, 81, pp. 112-121 (1993).

Lobo et al., "Addition of Peripheral Blood Stem Cells Collected Without Mobilization Techniques to Transplanted Autologous Bone Marrow Did Not Hasten Marrow Recovery Following Myeloablative Therapy", Bone Marrow Transplantation, 8, pp. 389-392 (1991).

Magrin et al., "Collection, Processing and Storage of Peripheral Blood Stem Cells (PBSC)", Hematologica, 76, Suppl. 1, pp. 55-57 (1991).

*Papayannopoulou et al., "Peripheralization of hemopoietic Progenitors in Primates Treated with Anti-VLA4 Integrin", Proc. Natl. Acad. Sci. USA, 90, pp. 9374-9378 (1993).

Rowe et al., "Hemopoietic Growth Factors: A Review", J. Clin. Pharmacol., 32, pp. 486-501 (1992)

Ryan et al., "Inhibition of Human Bone Marrow Lymphoid Progenitor Colonies by Antibodies to VLA Integrins", J. Immunol., 149, 11, pp. 3759-64 (1992).

*Siena et al., "Circulation of CD34+ Hematopoietic Stem Cells in the Peripheral Blood of High-Dose

Cyclophosphamide-Treated Patients: Enhancement by Intravenous Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor", Blood, 74, No. 6, pp. 1905-1914 (1989).

Simmons et al., "Vascular Cell Adhesion Molecule-1 Expressed by Bone Marrow Stromal Cells Mediates the Binding of Hematopoietic Progenitor Cells", Blood, 80, 388-395 (1992).

*Stewart et al., "Post-5-Fluorouracil Human Marrow: Stem Cell Characteristics and Renewal Properties After Autologous Marrow Transplantation", Blood, 81, No. 9, pp. 2283-2289 (1993).

Teixido et al., "Human CD34+ Progenitor Cell Adhesion to Marrow Stroma is Mediated by VLA-4/VCAM and VLA5/Fibronectin", Blood, 78, Suppl. 1, p. 302a, abstract 1200 (1991).

Teixido et al., "Role of 1 and 2 Integrins in the Adhesion of Human CD34^{hi} Stem Cells to Bone Marrow Stroma", J. Clin. Invest., 90, pp. 358-367 (1992).


Williams et al., "Fibronectin and VLA-4 in hematopoietic Stem Cells-Microenvironment Interactions", Nature, 352, pp. 438-441 (1991).

Pursuant to 37 C.F.R § 1.98(d), applicant has enclosed copies of the above documents (marked with an asterisk(*)) that were not either cited by or submitted to the Examiner in United States Application Serial No. 07/977,702 from which the instant application claims priority.



Applicant respectfully requests (1) that the Examiner fully consider these documents during the course of examination of this application; (2) that the "Notice of References Cited" issued in this application list these documents; and (3) that any patent issuing from the application contain a list of these documents.

Respectfully submitted,




James F. Haley, Jr. (Reg. No. 27,794)
Immac J. Thampoe (Reg. No. 36,322)
Attorneys for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000

I Herby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to: ASSISTANT
COMMISSIONER FOR PATENTS
WASHINGTON D.C. 20231, on


November 3, 1995
Thomas Guindres
Name of Person Signing

Signature of Person Signing